|
||||||||||
 |
|
|
|
|
|
|
|
|
Lucknow gets Asia's first human DNA bank
11 June 2008
Asia's first and the world's second human DNA bank has been set up at the Biotech Park in Lucknow district of Uttar Pradesh. One of the most important functions to be performed by the bank will be of DNA Identification System (DIS). This in turn will facilitate establishing identity of individuals within a few seconds.
The members of the DNA bank will receive a microchip based DNA card containing information of their fingerprints, and anthropological details. The DNA park has been developed under a public private partnership by IQRA Biotech Services (IBS) and Lucknow's Biotech Park.
Biocon hoping for top slot in nephrology
5 June 2008
After completing over a year in the growing segment of nephrology, Biocon Ltd is hoping to be the top domestic player in the segment in next 4-5 years. The nephrology range with six branded products was launched in March 2007. These formulations at present contribute about 8 % of the company’s revenues and are expected to grow to 15% next year.
KCP Biotech to merge with parent company
1 June 2008
KCP Biotech Ltd, the wholly owned subsidiary of KCP LTD, is to merge with the parent company. According to Chairman and Managing Director, KCP Ltd., Mr. V.L. Dutt the merger would enable KCP to better support the biotech operations for manufacturing natural food colours and flavours. With this merger, the biotech operations would now be a division of KCP just as cement and engineering.
3rd Annual BioPharma Asia Conference 2008
The 3rd Annual Biopharma Asia Conference is going to be held on the 8th of September at Sheraton Towers Hotel, Singapore. The three-day event will continue till 11th of September 2008.
Featured as one of the most important bioprocessing events in Asia this year, the program will provide case studies and content-rich information to implement in your unit.
The list of plenary speakers for the conference include Dr. Michael D. Kowolenko, Senior Vice President, Wyeth Biotech TO& PS, USA, Dr. Tim Oldham President, Asia Pacific, Hospira, Australia, and Dr. Xiaoming (Jerry) Yang Scientific Director, Process and Analytical Sciences, Amgen Inc., USA amongst others.
 |
Sun Pharma plans to acquire all outstanding shares of Taro
30 June 2008
As the continuous fight between Sun Pharm and Taro is showing no sign of coming to an end, Mumbai-based Sun Pharma initiated an open offer to acquire the Israeli firm Taro completely.
Sun is planning to acquire all outstanding ordinary shares of Taro, including all its founders' shares as well. For this, Sun’s subsidiary Alkaloida Chemical Company Exclusive Group Ltd. has launched a tender offer at a price of US$ 7.75 per share.
Itero Biopharma partners Biological E.
26 June 2008
Itero Biopharmaceuticals Inc has inked a broad-ranging partnership with the Hyderabad-based Biological E. Ltd (BE). The focus of the partnership would be on worldwide development and manufacture of value-added, follow-on and novel proteins and antibodies.
Bal Pharma’s Uttarkhand plant to complete soon
25 June 2008
Bal Pharma Ltd’s new manufacturing plant in Uttarkhand is nearing completion and conforms to USFDA (US Food and Drug Administration) and the UK MCHRA guidelines. The company is focussing on a four-fold revenue growth to US$ 75 million by the end of 2010.
NPPA modified price guidelines, drug makers under Govt. scrutiny
25 June 2008
It has now been made imperative for drug manufacturers to get a price approval from the government before introducing new brands containing price-controlled ingredients in the domestic market. Defying this may lead them to face legal action.
The National Pharmaceutical Pricing Authority (NPPA) has modified its internal price enforcement guidelines and companies launching new brands without a price approval for a second time will automatically qualify for prosecution under the revised guidelines.
|
Unichem’s formulation plant gets US FDA nod
23 June 2008
Unichem Laboratories Ltd has announced that it has received approval from the US Food and Drug Administration for its formulations plant in the northern state of Uttar Pradesh.
Lupin, Ascend enters promotion pact
23 June 2008
Pharmaceutical firm Lupin has entered in a promotion agreement with Ascend Therapeutics Inc to promote its Suprax 400mg tablets in the US.
Selling family stakes was important for Ranbaxy’s growth
22 June 2008
Ranbaxy CEO, Mr. Malvinder Mohan Singh said that the sale of his family’s 34.8 % stake in Ranbaxy to Daiichi Sankyo was important for the pharmaceutical company to grow. Daiichi Sankyo has also offered another 20 % stake, which could make the deal worth up to $4.6 billion. Mr. Singh will stay on as CEO for at least five years.
According to Mr. Malvinder Singh, Healthcare and financial services are two areas where the family has existing businesses and would like make further investments.
Glenmark’s trandolapril tab launched in US
20 June 2008
Glenmark Pharmaceuticals Ltd’ unit, Glenmark Generics Ltd, has got the approval from the US Food and Drug Administration and has started selling the trandolapril tablets in the United States.
|
Drug suppliers to get scrutinized by US FDA
19 June 2008
A US senator has claimed that drugmakers are taking advantage of lower safety standards in countries like China and India. The senator has therefore asked the US Food & Drug Administration (FDA) to probe into outsourcing of pharmaceutical ingredients to China & India.
Overcharging Pharma companies to face land arrears
18 June 2008
Drug makers that are overcharging consumers may now have to fear state district administration since the National Pharmaceutical Pricing Authority (NPPA) has revised its internal guidelines so that overcharging cases beyond a particular amount are automatically referred to district collectors administering the regions where companies have assets.
Maneesh Pharma acquires 51% stake in US firm, Synovics
18 June 2008
Maneesh Pharmaceuticals has acquired over 51% stake in US-based Synovics Pharmaceuticals for an undisclosed amount. Synovics is a speciality pharma firm with a focus in OTC (over-the-counter) and branded drugs and have a strong distribution network in the US.
High import costs led to shortages in Pharma cos
17 June 2008
Ingredients imported from China are getting costlier since the Chinese suppliers need to comply with stricter pollution control norms in the wake of Olympic Games later this year. Growing import costs are making it unviable for Indian pharmaceutical companies leading to an estimate that almost 20% drugs may go off the shelf by next month. Producers of active pharmaceutical ingredient (API) have said they may even have to raise prices in the wake of rising input costs
|
Lupin's anti-depressant drug gets US approval
16 June 2008
Lupin Ltd. has got approval from the US drug administration for marketing an anti-depressant drug in USA. Lupin said the green-signal for its anti-depressant Escitalopram Oxalate tablets was given to its US subsidiary Lupin Pharmaceuticals.
Report says India more mature for drug discovery than China
15 June 2008
According to a report made by US-based Ewing Marion Kauffman Foundation, the various latest research and development initiatives in the pharma sector has made India a more mature place for chemistry and drug discovery activities than China.
Western Pharma companies shift work to India, China
12 June 2008
A new study says that various factors like cost pressures, the need to tap global talent, and growth opportunities in emerging markets has led western pharmaceutical companies to shift substantial manufacturing and clinical – trial works to India and China. Big pharmaceutical companies are now counting these two countries for advanced research and development.
Aurobindo got USFDA nod for Zaleplon
10 June 2008
Aurobindo Pharma Ltd received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zaleplon capsules in 5 mg and 10 mg dosages for the treatment of insomnia.
|